The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials
Abstract
Background In our 2015 systematic review and meta-analysis of cardiovascular outcome trials for glucose-lowering drugs or strategies in people with or at risk of type 2 diabetes, we reported a modest reduction in atherosclerotic cardiovascular events and an increased risk of heart failure, but with heterogeneous effects by drug or intervention type. In view of the completion of many large cardiovascular outcome trials since our previous analysis, including trials of novel drugs that have shown beneficial effects on cardiovascular outcomes, we aimed to update our analysis to incorporate these findings. Methods We did an updated systematic review and meta-analysis of large cardiovascular outcome trials of glucose-lowering drugs or strategies in people with or at risk of type 2 diabetes. We searched Ovid MEDLINE, PubMed, and the Cochrane Central Register of Controlled Trials databases for reports of trials published from Nov 15, 2013 to Nov 20, 2019. We included randomised controlled trials with a minimum of 1000 adults (aged ≥19 years) with or at risk of type 2 diabetes, with major adverse cardiovascular events (MACE) as an outcome, and with follow-up of at least 12 months. We excluded trials with patients enrolled with an acute cardiovascular event. The main outcomes of interest were MACE (generally defined as a composite of cardiovascular death, myocardial infarction, or stroke) and heart failure. We calculated pooled risk ratios (RRs) and 95% CIs with inverse-variance random-effects models, did meta-regression to analyse treatment effects per difference in bodyweight achieved, and explored results stratified by baseline subgroups. Findings Our updated search yielded 30 eligible trials (n=225 305). The mean age of participants was 63·0 years (SD 8·4) and mean duration of diabetes was 9·4 years (6·6). After a mean follow-up of 3·8 years (1·8), 23 016 (10·2%) participants had MACE and 8169 (3·6%) had a heart failure event. Glucose-lowering drugs or strategies lowered the risk of MACE compared with standard care or placebo (RR 0·92, 95% CI 0·89-0·95, p<0·0001), with no overall effect on the risk of heart failure (0·98, 0·90-1·08, p=0·71). However, across drug classes or strategies, the magnitude and directionality of RR for heart failure varied (p interaction<0·0001), with meta-regression showing that a decrease in bodyweight of 1 kg was associated with a 5·9% (3·9-8·0) relative decrease in the risk of heart failure (p<0·0001). Among trials that assessed drug classes or strategies associated with weight loss (intensive lifestyle changes, GLP-1 receptor agonists, or SGLT2 inhibitors), the risk reduction for MACE was consistent among participants with (0·87, 0·83-0·92) and without (0·92, 0·83-1·02) established cardiovascular disease at baseline (p interaction=0·33). For heart failure, the RR for drug classes or strategies associated with weight loss was consistent among participants with (0·80, 0·73-0·89) and without (0·84, 0·74-0·95) cardiovascular disease at baseline (p interaction=0·63). Interpretation Glucose-lowering drugs or strategies overall reduced the risk of fatal and non-fatal atherosclerotic events. The effect on heart failure was neutral overall but varied substantially by intervention type, with interventions associated with weight loss showing a beneficial effect. The cardiovascular and heart failure benefits of interventions associated with weight loss might extend to patients without established cardiovascular disease. Funding None.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“a recent meta-analysis of all current CVOTs, showed that GLP-1RAs as a group were associated with a (non-significant) reduction in HF”
From Safety of Semaglutide (2021) · cites this paper as [104]
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Self-citationEffects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationDapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Self-citationCanagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Cited by
Sorted by citations
The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments
Targher, G., Corey, K. E., Byrne, C. D., & Roden, M. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00448-y · Cited by 850
Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes
Gerstein, H. C., Sattar, N., Rosenstock, J., Ramasundarahettige, C., Pratley, R., Lopes, R. D., Lam, C. S. P., Khurmi, N. S., Heenan, L., Del Prato, S., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2108269 · Cited by 829
Syn, N. L., Cummings, D. E., Wang, L. Z., Lin, D. J., Zhao, J. J., Loh, M., Koh, Z. J., Chew, C. A., Loo, Y. E., Tai, B. C., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00591-2 · Cited by 521
Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus
Ferguson, D., & Finck, B. N. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00507-z · Cited by 520
Global pandemics interconnected — obesity, impaired metabolic health and COVID-19
Stefan, N., Birkenfeld, A. L., & Schulze, M. B. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-00462-1 · Cited by 452
Oduro, P. K., Zheng, X., Wei, J., Yang, Y., Wang, Y., Zhang, H., Liu, E., Gao, X., Du, M., & Wang, Q. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.05.011 · Cited by 349
Smits, M. M., & Van Raalte, D. H. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.645563 · Cited by 332
Mantovani, A., Byrne, C. D., & Targher, G. (2022) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(21)00261-2 · Cited by 230
Liu, Z., Ma, X., Ilyas, I., Zheng, X., Luo, S., Little, P. J., Kamato, D., Sahebkar, A., Wu, W., Weng, J., et al. (2021) · Theranostics · doi:10.7150/thno.54498 · Cited by 155
Dyslipidemia, Diabetes and Atherosclerosis: Role of Inflammation and ROS-Redox-Sensitive Factors
Hasheminasabgorji, E., & Jha, J. C. (2021) · Biomedicines · doi:10.3390/biomedicines9111602 · Cited by 126
Tsai, W.-H., Chuang, S.-M., Liu, S.-C., Lee, C.-C., Chien, M.-N., Leung, C.-H., Liu, S.-J., & Shih, H.-M. (2021) · Scientific Reports · doi:10.1038/s41598-021-94945-4 · Cited by 113
Beta-Cell Mass in Obesity and Type 2 Diabetes, and Its Relation to Pancreas Fat: A Mini-Review
Inaishi, J., & Saisho, Y. (2020) · Nutrients · doi:10.3390/nu12123846 · Cited by 119
Structural requirements of flavonoids for the selective inhibition of α-amylase versus α-glucosidase
Lim, J., Ferruzzi, M. G., & Hamaker, B. R. (2021) · Food Chemistry · doi:10.1016/j.foodchem.2021.130981 · Cited by 100
Strain, W. D., Frenkel, O., James, M. A., Leiter, L. A., Rasmussen, S., Rothwell, P. M., Sejersten Ripa, M., Truelsen, T. C., & Husain, M. (2022) · Stroke · doi:10.1161/strokeaha.121.037775 · Cited by 93
Self-citationYu, M., Zhu, S., Huang, D., Tao, X., & Li, Y. (2023) · Food Chemistry · doi:10.1016/j.foodchem.2023.137499 · Cited by 72
Natali, A., Nesti, L., Tricò, D., & Ferrannini, E. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01385-5 · Cited by 70
Prevention of cardiorenal complications in people with type 2 diabetes and obesity
Drucker, D. J. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2023.12.018 · Cited by 68
Armillotta, M., Angeli, F., Paolisso, P., Belmonte, M., Raschi, E., Dalmazi, G. D., Amicone, S., Canton, L., Fedele, D., Suma, N., et al. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108861 · Cited by 76
The Potentially Modifiable Risk Factor in Idiopathic Intracranial Hypertension
Mollan, S. P., Tahrani, A. A., & Sinclair, A. J. (2021) · Neurology Clinical Practice · doi:10.1212/cpj.0000000000001063 · Cited by 60
Janež, A., & Fioretto, P. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01104-z · Cited by 65
Advancements in risk stratification and management strategies in primary cardiovascular prevention
Barkas, F., Şener, Y. Z., Golforoush, P. A., Kheirkhah, A., Rodríguez‐Sánchez, E., Novák, J., Apellániz-Ruiz, M., Akyea, R. K., Bianconi, V., Ceasovschih, A., et al. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.117579 · Cited by 61
Zare, F., Ataollahi, E., Mardaneh, P., Sakhteman, A., Keshavarz, V., Solhjoo, A., & Emami, L. (2024) · Scientific Reports · doi:10.1038/s41598-024-58485-x · Cited by 60
Cahn, A., Wiviott, S. D., Mosenzon, O., Murphy, S. A., Goodrich, E. L., Yanuv, I., Rozenberg, A., Wilding, J. P. H., Leiter, L. A., Bhatt, D. L., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14179 · Cited by 51
Self-citationCherney, D. Z. I., Udell, J. A., & Drucker, D. J. (2021) · Med · doi:10.1016/j.medj.2021.10.004 · Cited by 54
Self-citationThe Role of SGLT2 Inhibitors in Atherosclerosis: A Narrative Mini-Review
de Mortanges, A. P., Salvador, D., Laimer, M. W., Muka, T., Wilhelm, M., & Bano, A. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.751214 · Cited by 52
D’Andrea, E., Kesselheim, A. S., Franklin, J. M., Jung, E. H., Hey, S. P., & Patorno, E. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01133-1 · Cited by 46
Beneficial Effects of Vitamin K Status on Glycemic Regulation and Diabetes Mellitus: A Mini-Review
Ho, H., Komai, M., & Shirakawa, H. (2020) · Nutrients · doi:10.3390/nu12082485 · Cited by 48
Association of Baseline HbA1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58
Cahn, A., Wiviott, S. D., Mosenzon, O., Goodrich, E. L., Murphy, S. A., Yanuv, I., Rozenberg, A., Bhatt, D. L., Leiter, L. A., McGuire, D. K., et al. (2022) · Diabetes Care · doi:10.2337/dc21-1744 · Cited by 42
Self-citationMak, K.-H., Vidal-Petiot, E., Young, R., Sorbets, E., Greenlaw, N., Ford, I., Tendera, M., Ferrari, R., Tardif, J.-C., Udell, J. A., et al. (2022) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab011 · Cited by 39
Self-citationMata‐Cases, M., Franch‐Nadal, J., Real, J., Vlacho, B., Gómez‐García, A., & Mauricio, D. (2021) · Primary care diabetes · doi:10.1016/j.pcd.2021.02.003 · Cited by 40
Metformin: new applications for an old drug
Naseri, A., Sanaie, S., Hamzehzadeh, S., Sahebari, S. S., Hosseini, M., Gholipour-khalili, E., Rezazadeh-Gavgani, E., Majidazar, R., Seraji, P., Daneshvar, S., et al. (2022) · Journal of Basic and Clinical Physiology and Pharmacology · doi:10.1515/jbcpp-2022-0252 · Cited by 44
Sakurai, S., Jojima, T., Iijima, T., Tomaru, T., Usui, I., & Aso, Y. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107703 · Cited by 39
Oral GLP-1 analogue: perspectives and impact on atherosclerosis in type 2 diabetic patients
Saraiva, J. F. K., & Franco, D. R. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01417-0 · Cited by 39
Gu, Y., Sun, L., He, Y., Yang, L., Deng, C., Zhou, R., Kong, T., Zhang, W., Chen, Y., Li, J., et al. (2023) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2023.2172397 · Cited by 36
Pintaudi, B., Scatena, A., Piscitelli, G., Frison, V., Corrao, S., Manicardi, V., Graziano, G., Rossi, M. C., Gallo, M., Mannino, D., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01251-4 · Cited by 35
Hill, M. A., Sowers, J. R., & Mantzoros, C. S. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154408 · Cited by 35
McAlister, F. A., Zheng, Y., Westerhout, C. M., Buse, J. B., Standl, E., McGuire, D. K., de Werf, F. V., Green, J. B., Armstrong, P. W., Holman, R. R., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1958 · Cited by 36
Jeong, H. E., Park, S., Noh, Y., Bea, S., Filion, K. B., Yu, O. H. Y., Jang, S. H., Cho, Y. M., Yon, D. K., & Shin, J. (2023) · BMC Medicine · doi:10.1186/s12916-023-02765-2 · Cited by 32
Shi, W., Xu, G., Gao, Y. J., Yang, H., Liu, T., Jia, Z., Li, H., Wei, Z., Hou, X., Chen, Y., et al. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.155404 · Cited by 33
Avogaro, A., Azzolina, D., Gregori, D., de Kreutzenberg, S., Fadini, G. P., & Mannucci, E. (2022) · International Journal of Cardiology · doi:10.1016/j.ijcard.2022.03.032 · Cited by 27
Li, X., Song, Y., Guo, T., Xiao, G., & Li, Q. (2022) · Diabetes & Metabolism · doi:10.1016/j.diabet.2022.101366 · Cited by 30
Villaschi, A., Ferrante, G., Cannata, F., Pini, D., Pagnesi, M., Corrada, E., Reimers, B., Mehran, R., Federici, M., Savarese, G., et al. (2024) · Clinical Research in Cardiology · doi:10.1007/s00392-023-02362-6 · Cited by 30
Consoli, A., Czupryniak, L., Duarte, R., Jermendy, G., Kautzky‐Willer, A., Mathieu, C., Melo, M., Mosenzon, O., Nobels, F. R. E., Παπάνας, Ν., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14102 · Cited by 26
Diaconu, C.-T., & Guja, C. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11175144 · Cited by 29
Khunti, K. K., & Aroda, V. R. (2022) · Diabetes Care · doi:10.2337/dci21-0064 · Cited by 24
Real-life underuse of SGLT2 inhibitors for patients with type 2 diabetes at high cardiorenal risk
Scheen, A. J. (2023) · Diabetes Epidemiology and Management · doi:10.1016/j.deman.2023.100184 · Cited by 25
Goldenberg, R. M., Ahooja, V., Clemens, K. K., Gilbert, J. D., Poddar, M., & Verma, S. (2021) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2020.09.005 · Cited by 23
Risk of Incident Heart Failure in Individuals With Early-Onset Type 2 Diabetes
Liu, J., Liu, S., Wang, J., Lee, J., Tang, J. I.-S., Gurung, R. L., Ang, K., Shao, Y. M., Subramaniam, T., Tang, W. E., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab620 · Cited by 22
Avogaro, A., de Kreutzenberg, S. V., Morieri, M. L., Fadini, G. P., & Prato, S. D. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00247-9 · Cited by 22
Hasebe, M., Yoshiji, S., Keidai, Y., Minamino, H., Murakami, T., Tanaka, D., Fujita, Y., Harada, N., Hamasaki, A., & Inagaki, N. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01773-z · Cited by 25
Rodriguez‐Valadez, J. M., Tahsin, M., Masharani, U. B., Park, M., Hunink, M. G. M., Yeboah, J., Li, L., Weber, E. S., Berkalieva, A., Avezaat, L., et al. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.032463 · Cited by 21
Spatiotemporal control of GLP-1 receptor activity
Manchanda, Y., Bitsi, S., Kang, Y., Jones, B. J., & Tomás, A. (2020) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2020.07.003 · Cited by 21
Gerstein, H. C., Branch, K. R., Heenan, L., Prato, S. D., Khurmi, N. S., Lam, C. S. P., Pratley, R. E., Rosenstock, J., & Sattar, N. A. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14223 · Cited by 20
Wang, A., Li, Z., Zhuo, S., Gao, F., Zhang, H., Zhang, Z., Ren, G., & Ma, X. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.857952 · Cited by 19
Muzurović, E. M., & Mikhailidis, D. P. (2020) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248420941675 · Cited by 17
Inflammasomes as the molecular hub of cardiovascular-metabolic-immune comorbidity networks
Qian, X., Sun, J. M., Li, F., Li, X., Hu, X., Dong, N., & Li, G. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1690443 · Cited by 18
Longato, E., Camillo, B. D., Sparacino, G., Tramontan, L., Avogaro, A., & Fadini, G. P. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01414-3 · Cited by 15
SABOURET, P., BOCCHINO, P. P., ANGELINI, F., D’ASCENZO, F., GALATI, G., FYSEKIDIS, M., DE FERRARI, G. M., FISCHMAN, D. L., BHATT, D. L., & BIONDI-ZOCCAI, G. (2023) · Minerva Cardiology and Angiology · doi:10.23736/s2724-5683.22.05900-2 · Cited by 14
Bechmann, L. E., Emanuelsson, F., Nordestgaard, B. G., & Benn, M. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvad122 · Cited by 14
Grenet, G., Mekhaldi, S., Mainbourg, S., Auffret, M., Cornu, C., Cracowski, J., Gueyffier, F., Lega, J., & Cucherat, M. (2021) · Diabetes Care · doi:10.2337/dc20-2018 · Cited by 14
Sodium-Glucose Cotransporter-2 Inhibitors in Vascular Biology: Cellular and Molecular Mechanisms
Xiao, L., Nie, X., Cheng, Y., & Wang, N. (2021) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07216-9 · Cited by 16
Muzurović, E. M., Dragnić, S., Medenica, S., Smolović, B., Bulajić, P., & Mikhailidis, D. P. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107619 · Cited by 16
The Effects of Metformin on Weight Loss, Cardiovascular Health, and Longevity
Pillai, A. A., Melo, L., Frishman, W. H., & Aronow, W. S. (2024) · Cardiology in Review · doi:10.1097/crd.0000000000000832 · Cited by 17
Cintra, R. M. R., Nogueira, A. C. C., Bonilha, I., Luchiari, B., Coelho‐Filho, O. R., Coelho, O. R., Schwartzmann, P. V., Muscellie, E., Nadruz, W., de Carvalho, L. S. F., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab428 · Cited by 12
Zheng, H., Sigal, R. J., Coyle, D., Bai, Z., Johnston, A., Elliott, J., Hsieh, S., Kelly, S., Chen, L., Skidmore, B., et al. (2021) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3515 · Cited by 13
Chang, H., Chen, Y., Kuo, T., Lin, Y., Chien, K., Chang, H., Hung, C., & Chung, F. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.032397 · Cited by 13
Wang, L., Xin, Q., Wang, Y., Chen, Z., Yuan, R., Yu, M., Zhang, G., & Cong, W. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105765 · Cited by 12
Song, Z., Tang, Y., Peng, M., Han, R., & He, P. (2025) · Pharmaceuticals · doi:10.3390/ph18091261 · Cited by 15
Scheen, A. J. (2023) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2023.2279193 · Cited by 11
Feng, Z., Tong, W. K., Zhang, X., & Tang, Z. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1226778 · Cited by 10
Wang, Z., Zhang, L., Wang, M., Ding, Z., Ren, D., & Duan, S. (2024) · eFood · doi:10.1002/efd2.144 · Cited by 10
Chen, B., Tao, L., Tian, M., & Ji, Z. (2025) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2025.01.056 · Cited by 10
Coenzyme Q10 for Diabetes and Cardiovascular Disease: Useful or Useless?
Renke, G., Pereira, M. B., & Renke, A. (2022) · Current Diabetes Reviews · doi:10.2174/1573399818666220429101336 · Cited by 12
Wang, J., Liu, W.-J., & Lee, W. (2021) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223211026391 · Cited by 10
The expanding role of semaglutide: beyond glycemic control
Zarei, M., Sabetkasaei, M., Mozafari, M., & Zaeri, S. (2025) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01663-z · Cited by 10
Robinson, J. G., Jayanna, M. B., Merz, C. N. B., & Stone, N. J. (2020) · PLoS ONE · doi:10.1371/journal.pone.0240166 · Cited by 9
Sciannameo, V., Berchialla, P., Avogaro, A., Fadini, G. P., DARWIN-T2D Network, Consoli, A., Formoso, G., Grossi, G., Pucci, A., Sesti, G., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01300-y · Cited by 9
Seo, B., Su, J., & Song, Y. (2022) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-022-03327-w · Cited by 9
Slingerland, S. R., Schulz, D. N., van Steenbergen, G. J., Hamad, M. A. S., Kisters, J. M. H., Timmermans, M. J. C., Teeuwen, K., Dekker, L., & van Veghel, D. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02356-2 · Cited by 8
Fadini, G. P., Disoteo, O., Candido, R., Bartolo, P. D., Laviola, L., & Consoli, A. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01012-2 · Cited by 8
Diallo, A., Villard, O., Carlos‐Bolumbu, M., Duc, P., & Galtier, F. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16561 · Cited by 7
Uthman, O. A., Al-Khudairy, L., Nduka, C. U., Court, R. A., Enderby, J., Anjorin, S., Mistry, H., Meléndez‐Torres, G. J., Taylor‐Phillips, S., & Clarke, A. (2023) · Health Technology Assessment · doi:10.3310/gjtr5006 · Cited by 8
Xia, W., Yu, H., Lei, X., & Wen, P. (2024) · Medicine · doi:10.1097/md.0000000000037432 · Cited by 7
Lumbers, R. T., Katsoulis, M., Henry, A., Mordi, I. R., Lang, C. C., Hemingway, H., Langenberg, C., Holmes, M. V., & Sattar, N. A. (2020) · medRxiv · doi:10.1101/2020.09.23.20200360 · Cited by 7
Lou, W., Cheng, Q., Liang, Y., & Ding, X. (2021) · International Journal of General Medicine · doi:10.2147/ijgm.s337874 · Cited by 6
Morieri, M. L., Raz, I., Consoli, A., Rigato, M., Lapolla, A., Broglio, F., Bonora, E., Avogaro, A., Fadini, G. P., for the DARWIN-FUP network, et al. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-022-02002-2 · Cited by 6
Millar, B., & de Gaetano, M. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1125858 · Cited by 7
Non-alcoholic fatty liver disease is associated with an increased risk of type 2 diabetes
Loosen, S. H., Krieg, S., Krieg, A. H., Qvartskhava, N., Luedde, T., Kostev, K., & Roderburg, C. (2023) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002555 · Cited by 7
MacIsaac, R. J. (2021) · Future Cardiology · doi:10.2217/fca-2020-0210 · Cited by 6
Chen, Z., Meng, H., Guo, Y., Sun, H., Zhang, W., Yu, C., & Hou, S. (2024) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2024.108136 · Cited by 5
Misceo, D., Mocciaro, G., D’Amore, S., & Vacca, M. (2024) · Nutrition & Metabolism · doi:10.1186/s12986-024-00871-3 · Cited by 6
Wang, J., Li, D., Ju, W., & Wang, H. (2022) · Journal of Vascular Diseases · doi:10.3390/jvd1010007 · Cited by 5
Wang, W., Liu, R., Zhu, Y., Wang, L., Tang, Y., Dou, B., Tian, S., & Wang, F. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1195149 · Cited by 5
Shouldn’t Preventing Type 2 Diabetes Also Prevent Its Long-Term Consequences?
Gerstein, H. C. (2022) · Circulation · doi:10.1161/circulationaha.122.060026 · Cited by 5
Longato, E., Camillo, B. D., Sparacino, G., Avogaro, A., & Fadini, G. P. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01600-x · Cited by 4
Brockmeyer, M., Fell, M., Parco, C., Hoss, A., Vargas, K. G., Wies, E., Lin, Y., Heinen, Y., Chernyak, N., Icks, A., et al. (2025) · BMC Cardiovascular Disorders · doi:10.1186/s12872-025-04599-7 · Cited by 4
Avogaro, A., & Fadini, G. P. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30044-9 · Cited by 4
Krittayaphong, R., Aroonsiriwattana, S., Ngamjanyaporn, P., Patmuk, T., Kaewkumdee, P., & for the COOL‐AF Investigators (2021) · International Journal of Clinical Practice · doi:10.1111/ijcp.14671 · Cited by 4
Tirzepatide for the Treatment of Heart Failure in Type 2 Diabetes Mellitus: (SUR)PASS, or Not?
Patoulias, D., Dimosiari, A., & Fragakis, N. (2023) · Future Cardiology · doi:10.2217/fca-2022-0112 · Cited by 4
Çöllüoğlu, T., Çelik, A., Ata, N., Ural, D., Şahin, A., Ülgü, M. M., Kanık, E. A., Birinci, Ş., & Yılmaz, M. B. (2024) · International Journal of Cardiology · doi:10.1016/j.ijcard.2024.132109 · Cited by 4
Metadata
- Authors
- Ghosh-Swaby, O. R., Goodman, S. G., Leiter, L. A., Cheng, A., Connelly, K. A., Fitchett, D., Jüni, P., Farkouh, M. E., & Udell, J. A.
- Affiliations
- St. Michael's Hospital (CA)
- University Health Network (CA)
- Corresponding author
- Udell, Jacob A
- ORCID
- Venue
- The Lancet Diabetes & Endocrinology
- Publisher
- Elsevier BV
- Published
- 2020-05
- Volume
- 8
- Issue
- 5
- Pages
- 418-435
- ISSN
- 2213-8587 (ISSN-L)
- OpenAlex
- W3019508129
- Cited by
- 159
- References
- 49
- Citations by year
- 2026: 7 · 2025: 12 · 2024: 34 · 2023: 26 · 2022: 21 · 2021: 38 · 2020: 20
- FWCI
- 4.02
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Lancet Diabetes & Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of Toronto
- Women's College Research Institute
- Heart and Stroke Foundation of Canada (-15-0009034)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- antidiabetic drugs, type 2 diabetes, atherosclerotic cardiovascular disease, major adverse cardiovascular events, heart failure, cardiovascular outcome trials, weight loss, SGLT2 inhibitors, GLP-1 receptor agonists, myocardial infarction, stroke, cardiovascular mortality
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Sodium-Glucose Transporter 2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, Aged, Diabetes Mellitus, Type 2, Heart Failure, Humans, Hypoglycemic Agents, Middle Aged, Atherosclerosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
